### ü´Å Pulmonary Medicine: Roflumilast for COPD with Chronic Bronchitis

#### ‚úÖ True Statements
1. **Roflumilast**, a **selective phosphodiesterase-4 inhibitor**, is used as adjunctive therapy in patients with **severe chronic obstructive pulmonary disease (COPD)** with a **chronic bronchitis phenotype** and a **history of recurrent exacerbations** despite other therapies.
2. **Roflumilast** has been shown to **improve lung function** and **reduce risk for and frequency of exacerbations** in patients with severe COPD and chronic bronchitis.
3. Common adverse effects of **roflumilast** include **diarrhea**, **nausea**, **weight loss**, and **headache**.
4. **Roflumilast** is **contraindicated** in patients with **liver impairment** and has **significant drug interactions**.
5. **Oral glucocorticoids** (e.g., **prednisone**) are reserved for **limited periodic use** in treating **acute COPD exacerbations** and are **not recommended** for long-term management due to limited benefit and significant adverse effects.
6. **Methylxanthines** (e.g., **theophylline**) provide only **modest benefit** in COPD and are associated with **toxicity**, limiting their use.
7. **Trimethoprim-sulfamethoxazole** has **not been shown** to prevent COPD exacerbations and is **not an appropriate therapy** for this purpose.

#### üí¨ Extra
1. Roflumilast is particularly indicated for patients with **severe COPD (forced expiratory volume in 1 second [FEV‚ÇÅ] <50% predicted)**, chronic bronchitis symptoms, and frequent exacerbations.

#### üè∑Ô∏è Tags
#PulmonaryMedicine #COPD #ChronicBronchitis #Roflumilast #AmbulatoryCare

#### üìö Reference
Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2025 Report. https://goldcopd.org/2025-gold-report/. Accessed May 20, 2025.

#### üÜî Question ID
PMQQQ24009

#### üïí Last Updated
June 2025

---

#### üìñ Related Text
MKSAP 19: Pulmonary Medicine ‚Äî Airways Disease, Chronic Obstructive Pulmonary Disease, Management of COPD, Pharmacologic Therapy for COPD, Roflumilast

---

### üìò Related Text Derivations

#### ‚úÖ True Statements ‚Äî Roflumilast
1. **Roflumilast** is a **selective phosphodiesterase-4 inhibitor** used to **reduce the frequency of exacerbations** in patients with **severe COPD (FEV‚ÇÅ <50% predicted)** who primarily have **symptoms of chronic bronchitis**.
2. **Roflumilast** should be considered in patients with **at least two COPD exacerbations** or **one exacerbation requiring hospitalization** within the past year.

#### üí¨ Extra
1. This aligns with **GOLD recommendations** for adjunctive therapy in high-risk COPD with chronic bronchitis phenotype.

#### üè∑Ô∏è Tags
#COPD #ChronicBronchitis #Roflumilast #Exacerbations #PulmonaryMedicine
